tradingkey.logo

Ginkgo Bioworks Holdings Inc

DNA
查看详细走势图
10.100USD
+1.800+21.63%
收盘 02/06, 16:00美东报价延迟15分钟
574.05M总市值
亏损市盈率 TTM

Ginkgo Bioworks Holdings Inc

10.100
+1.800+21.63%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+21.63%

5天

+12.60%

1月

+11.48%

6月

-17.82%

今年开始到现在

+21.54%

1年

-29.12%

查看详细走势图

TradingKey Ginkgo Bioworks Holdings Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Ginkgo Bioworks Holdings Inc当前公司基本面数据相对稳定,最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理,在生物技术与医疗研究行业排名168/392位。机构持股占比非常高,近一月多位分析师给出公司评级为卖出。最高目标价10.00。中期看,股价处于上升通道。近一个月,市场表现较强,基本面评分较高,但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Ginkgo Bioworks Holdings Inc评分

相关信息

行业排名
168 / 392
全市场排名
319 / 4521
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看空

Ginkgo Bioworks Holdings Inc亮点

亮点风险
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
估值合理
公司最新PE估值-1.63,处于3年历史合理位
机构减仓
最新机构持股31.33M股,环比减少0.01%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值189.53K

分析师目标

根据 4 位分析师
卖出
评级
10.000
目标均价
-0.99%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Ginkgo Bioworks Holdings Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Ginkgo Bioworks Holdings Inc简介

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
公司代码DNA
公司Ginkgo Bioworks Holdings Inc
CEOKelly (Jason)
网址https://investors.ginkgobioworks.com/
KeyAI